

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### **INSIDE INFORMATION**

#### **PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2021**

This announcement is made by CSPC Pharmaceutical Group Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC XNW**”) is a subsidiary of the Company and its shares are listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765). In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC XNW has published its 2021 Annual Report (“**Annual Report**”) on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the appendices of this announcement (the “**Appendices**”) which set out the principal financial information of CSPC XNW prepared in accordance with the PRC Accounting Standard for Business Enterprises for the year ended 31 December 2021.

The information in the Appendices is an extract of the Annual Report in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 17 March 2022

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.*

**APPENDIX I**  
**PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS**

*Unit: RMB (Yuan)*

	<b>2021</b>	<b>2020</b>	<b>Increase/decrease compared with last year</b>	<b>2019</b>
Revenue	1,431,987,664.46	1,317,414,122.08	8.70%	1,256,502,359.88
Net profit attributable to listed company's shareholders	317,071,430.99	299,835,756.44	5.75%	273,197,126.61
Net profit attributable to listed company's shareholders excluding the non-recurring gain/loss	298,498,249.98	263,188,500.07	13.42%	238,465,715.95
Net cash flows arising from operating activities	170,592,336.20	349,071,664.26	-51.13%	315,384,186.07
Basic earnings per share (Yuan/share)	0.581	0.549	5.83%	0.500
Diluted earnings per share (Yuan/share)	0.581	0.549	5.83%	0.500
Weighted average return on net assets	11.29%	11.82%	-0.53%	13.77%
	<b>End of 2021</b>	<b>End of 2020</b>	<b>Increase/decrease compared with the end of last year</b>	<b>End of 2019</b>
Total assets	3,225,776,209.68	2,954,902,756.59	9.17%	2,852,373,126.14
Net assets attributable to listed company's shareholders	2,952,078,874.74	2,678,111,938.23	10.23%	2,406,399,708.49

**APPENDIX II**  
**NON-RECURRING GAIN/LOSS ITEMS AND AMOUNTS**

*Unit: RMB (Yuan)*

Items	Amounts in 2021	Amounts in 2020	Amounts in 2019	Description
Gain/loss from disposal of non-current assets (including the part offset with the provision for impairment of assets)	-7,384,221.62	-430,725.37	-1,993,792.46	
Government grants recognised in profit or loss of current period (excluding those closely related to the company's business and continuously granted according to national standard quota of amount or volume under the national policies)	18,300,150.56	23,098,080.33	23,815,570.94	
Gain/loss from entrusted investments or assets management	10,618,573.52	22,978,112.40	21,808,271.60	
Non-operating income and expenses other than the above items	-898,539.74	-435,965.16	71,723.10	
Other items of profit or loss falling within the definition of non-recurring gains and losses	3,380,349.16	—	—	
<i>Less:</i> Impact of income tax	5,421,843.96	8,567,097.89	8,910,323.87	
Impact of minority interests (after tax)	21,286.91	-4,852.06	60,038.65	
<b>Total</b>	<b>18,573,181.01</b>	<b>36,647,256.37</b>	<b>34,731,410.66</b>	

**APPENDIX III**  
**SIGNIFICANT CHANGES IN PRINCIPAL ASSETS**

*Unit: RMB (Yuan)*

	End of 2021		Beginning of 2021		Percentage change	Description on significant changes
	Amount	Percentage of total asset	Amount	Percentage of total asset		
Cash and bank balances	1,231,863,277.33	38.19%	1,138,744,787.20	38.54%	-0.35%	
Trade receivables	269,787,693.48	8.36%	146,270,977.17	4.95%	3.41%	Increase in the balance of trade receivables at the end of the period mainly due to the increase in the price of caffeine products at the end of the fourth quarter.
Inventories	216,857,370.81	6.72%	110,998,816.18	3.76%	2.96%	Increase in the amount of goods in stock and raw materials mainly due to the increased goods in stock of overseas subsidiaries as well as higher raw material prices
Long-term equity investments	243,185,931.33	7.54%	235,874,486.64	7.98%	-0.44%	
Fixed assets	466,148,503.58	14.45%	572,657,618.28	19.38%	-4.93%	Decrease in the balance of fixed assets at the end of the period mainly due to the disposal of 100% equity interests of Hebei Zhongnuo Pharmaceutical Technology Co., Ltd. by the company.
Construction in progress	128,676,240.34	3.99%	154,828,065.57	5.24%	-1.25%	
Right-of-use assets	823,153.61	0.03%	1,646,307.21	0.06%	-0.03%	
Contract liabilities	17,909,145.81	0.56%	25,270,340.67	0.86%	-0.30%	
Lease liabilities			840,957.77	0.03%	-0.03%	